Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HEALTH CARE COSTS GREW 10.3% IN 1983, THE LOWEST ANNUAL

Executive Summary

HEALTH CARE COSTS GREW 10.3% IN 1983, THE LOWEST ANNUAL increase in a decade, according to new Health Care Financing Administration statistics. Overall health costs rose 12.5% in 1982, and 15.3% in 1980, the highest single-year inflation rate. Spending on all health services totaled $355 bil. in 1983, or about $1,459 for every U.S. citizen, HCFA said. Releasing the figures Oct. 10, HHS Secty. Heckler ascribed the slowing health inflation rate to lower general inflation, business and provider "cost-effective initiatives," and "reforms" in govt. programs. Hospital spending rose 9.1% in 1983, to $147 bil., HCFA reported. Hospital inflation was 14.9% the year before. Spending for physician services amounted to $69 bil. in 1983, an 11.7% increase compared to 12.8% the previous year. In Medicare and Medicaid, combined state and federal outlays totaled $91 bill., versus $83 bil. in 1982. The two programs paid $54 bil. for hospital care, up from $48 bil. in 1982, accounting for more than a third of all hospital payments and 29% of all health expenditures, HCFA said. Patients paid out-of-pocket for 27% of all health costs during 1983. HCFA plans to publish the estimates in the winter issue of Health Care Financing Review. Copies will be available in December for $4.75, from Superintendent of Documents, Govt. Printing Office, Washington, D.C. 20402.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel